Completed PHASE1 INTERVENTIONAL 2-arm NCT02448264

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BCX7353 in Healthy Subjects

Sponsor: BioCryst Pharmaceuticals

Conditions Hereditary Angioedema

Interventions BCX7353 Placebo to match BCX7353

Updated 5 times since 2017 Last updated: Jan 12, 2016 Started: May 31, 2015 Primary completion: Nov 30, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hereditary Angioedema and is currently completed. BioCryst Pharmaceuticals leads this study, which shows 5 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioCryst Pharmaceuticals

Data source: BioCryst Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ruddington, United Kingdom